Adjuvant Durvalumab Fails to Boost DFS in Resected NSCLC, Irrespective of PD-L1 Status
Adjuvant durvalumab did not improve disease-free survival in EGFR-/ALK-negative NSCLC patients, regardless of PD-L1 expression levels, according to the phase 3 BR.31 trial results presented at the 2024 ESMO Congress.
Related Clinical Trials
Reference News
Adjuvant Durvalumab Fails to Boost DFS in Resected NSCLC, Irrespective of PD-L1 Status
Adjuvant durvalumab did not improve disease-free survival in EGFR-/ALK-negative NSCLC patients, regardless of PD-L1 expression levels, according to the phase 3 BR.31 trial results presented at the 2024 ESMO Congress.